2 recruiting, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer TAR-210, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 220 | 2025-09-10 | 2026-11-03 |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer TAR-210, Gemcitabine, MMC - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 641 | 2024-04-18 | 2026-11-03 |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Erdafitinib, Vinflunine, Docetaxel - Urothelial Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 629 | 2018-03-23 | 2026-11-03 |
Non-Muscle Invasive Bladder Neoplasms (2)
Janssen Research & Development, LLC (3)
Argentina (3) · Belgium (3) · Brazil (3) · China (3) · France (3) · Germany (3) · Israel (3) · Italy (3) · Japan (3) · South Korea (3) · Spain (3) · United Kingdom (3) · United States (3) · Austria (2) · Greece (2)
2017 (1), 2023 (1)